Patents Assigned to DEKA BIOSCIENCES, INC.
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12145007
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: November 19, 2024
    Assignee: DEKA BIOSCIENCES INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12122814
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 22, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12121755
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 22, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12116390
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 15, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12116391
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 15, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12116389
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 15, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12116393
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 15, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12116392
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 15, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12110317
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 8, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12065473
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: August 20, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 12006346
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: June 11, 2024
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11629178
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 18, 2023
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11618775
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 4, 2023
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11613563
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: March 28, 2023
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11608368
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: March 21, 2023
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11572397
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: February 7, 2023
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11292822
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 5, 2022
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • IL-10 variant molecules conjugated with antibody variable domain regions
    Patent number: 10981966
    Abstract: The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 20, 2021
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • IL-10 variant molecules and methods of treating inflammatory disease
    Patent number: 10981965
    Abstract: The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 20, 2021
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Antibody-IL-10 fusion proteins
    Patent number: 10975134
    Abstract: The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 13, 2021
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm